# INfluenza VaccInation To Mitigate typE 1 Diabetes

> **NCT05585983** · PHASE4 · RECRUITING · sponsor: **Aarhus University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Vaxigrip Tetra Sanofi Pasteur Europe

## Key facts

- **NCT ID:** NCT05585983
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-14
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585983, "INfluenza VaccInation To Mitigate typE 1 Diabetes". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05585983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*